# Audrey Nosbaum

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/audrey-nosbaum/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,938 |
| Field | Dermatology and Skin Diseases |
| h-index | 29 |
| i10-index | 72 |
| OpenAlex ID | https://openalex.org/A5090861690 |
| ORCID iD | 0000-0003-2281-9052 |
| Works | 316 |

## Researcher papers

- [Regulatory T Cells in Skin Facilitate Epithelial Stem Cell Differentiation](https://scholariq.org/papers/regulatory-t-cells-in-skin-facilitate-epithelial-stem-cell-differentiation/)
- [A Wave of Regulatory T Cells into Neonatal Skin Mediates Tolerance to Commensal Microbes](https://scholariq.org/papers/a-wave-of-regulatory-t-cells-into-neonatal-skin-mediates-tolerance-to-commensal/)
- [Cutting Edge: Regulatory T Cells Facilitate Cutaneous Wound Healing](https://scholariq.org/papers/cutting-edge-regulatory-t-cells-facilitate-cutaneous-wound-healing/)
- [Allergic and irritant contact dermatitis](https://scholariq.org/papers/allergic-and-irritant-contact-dermatitis/)
- [When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council](https://scholariq.org/papers/when-does-atopic-dermatitis-warrant-systemic-therapy-recommendations-from-an/)
- [Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort](https://scholariq.org/papers/effectiveness-and-safety-of-dupilumab-for-the-treatment-of-atopic-dermatitis-in/)
- [Early-onset autoimmunity associated with SOCS1 haploinsufficiency](https://scholariq.org/papers/early-onset-autoimmunity-associated-with-socs1-haploinsufficiency/)
- [Regulatory T cells in skin are uniquely poised to suppress profibrotic immune responses](https://scholariq.org/papers/regulatory-t-cells-in-skin-are-uniquely-poised-to-suppress-profibrotic-immune/)
- [Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program](https://scholariq.org/papers/integrated-safety-analysis-of-abrocitinib-for-the-treatment-of-moderate-to/)
- [Hypersensitivity to oxaliplatin: clinical features and risk factors](https://scholariq.org/papers/hypersensitivity-to-oxaliplatin-clinical-features-and-risk-factors/)
- [The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey](https://scholariq.org/papers/the-economic-and-psychosocial-comorbidity-burden-among-adults-with-moderate-to/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Contact Dermatitis and Allergies](https://scholariq.org/topics/contact-dermatitis-and-allergies/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Drug-Induced Adverse Reactions](https://scholariq.org/topics/drug-induced-adverse-reactions/)
- [Food Allergy and Anaphylaxis Research](https://scholariq.org/topics/food-allergy-and-anaphylaxis-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.